Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 8/20 | 0.64 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.60 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2831609 | 0.85 | PI4KB (0.50) | PIK3CGPI4KBKDM4EALDH1A1MAPT | |
| SCHEMBL3513224 | 0.85 | PIK3CG (0.70) | PIK3CGPI4KBPIK3CDPIK3CAPIK3CB | |
| SCHEMBL2836277 | 0.85 | PIK3CG (0.70) | PIK3CGPI4KBPIK3CDPIK3CAPIK3CB | |
| SCHEMBL2839918 | 0.85 | PI4KB (0.51) | PIK3CGPI4KBPIK3CDPIK3CAPIK3CB | |
| SCHEMBL2833137 | 0.84 | PI4KB (0.52) | PIK3CGPI4KBKDM4EALDH1A1MAPT | |
| SCHEMBL4523424 | 0.83 | PI4KB (0.73) | PIK3CGPI4KBPIK3CDPIK3CAPIK3CB | |
| SCHEMBL2836878 | 0.83 | PI4KB (0.52) | PIK3CGPI4KBPIK3CDPIK3CAPIK3CB | |
| SCHEMBL2830807 | 0.82 | MAPT (0.51) | PI4KBKDM4EALDH1A1MAPTHTT | |
| SCHEMBL13135888 | 0.82 | PIK3CG (0.43) | PIK3CGPI4KBPIK3CDPIK3CAPIK3CB | |
| SCHEMBL2832412 | 0.82 | PIK3CG (0.46) | PIK3CGPI4KBPIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888546-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2015-07-08 | — | — | EP | claimed |
| US-7799814-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2010-09-21 | — | — | US | claimed |
| US-20080188531-A1 | Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial, viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries | LABORATOIRES SERONO SA (CH) | 2008-08-07 | — | — | US | claimed |
| EP-1888546-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2015-07-08 | — | — | EP | disclosed |
| EP-1888546-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2015-07-08 | — | — | EP | disclosed |
| US-7799814-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799814-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799814-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2010-09-21 | — | — | US | disclosed |
| US-20080188531-A1 | Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial, viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries | LABORATOIRES SERONO SA (CH) | 2008-08-07 | — | — | US | disclosed |
| US-20080188531-A1 | Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial, viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries | LABORATOIRES SERONO SA (CH) | 2008-08-07 | — | — | US | disclosed |
| US-20080188531-A1 | Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial, viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries | LABORATOIRES SERONO SA (CH) | 2008-08-07 | — | — | US | disclosed |
| EP-1888546-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006125805-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188531-A1 | Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial, viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries | PDGFRA, PDGFRB, PF4 | PIK3CG 1076/4885PI4KB 1541/4885PIK3CD 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.